IMARC Group, a leading market research company, has recently releases report titled “GCC Vaccine Market Report by Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, and Others), Patient Type (Paediatric, Adult), Indication (Bacterial Diseases, Viral Diseases), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, and Others), Product Type (Multivalent Vaccine, Monovalent Vaccine), Treatment Type (Preventive Vaccine, Therapeutic Vaccine), End User (Hospitals, Clinics, Vaccination Centres, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales, and Others), and Country 2024-2032”. The study provides a detailed analysis of the industry, including the GCC vaccine market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big is the GCC Vaccine Market?
The GCC vaccine market size reached US$ 365.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 546.7 Million by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032.
Request for a PDF sample of this report: https://www.imarcgroup.com/gcc-vaccine-market/requestsample
GCC Vaccine Market Overview:
Vaccines are biologically prepared agents that provide active acquired immunity to specific infectious diseases. They contain microorganisms or viruses in a weakened, live, or killed state, or proteins or toxins from the organism. In stimulating the body's adaptive immunity, they help prevent morbidity from future infections. The types of vaccines include live attenuated, inactivated, subunit, recombinant, conjugate, and mRNA vaccines, each tailored for specific diseases and patient groups. The advantages of vaccination are profound, encompassing both health and economic benefits. By reducing the spread of diseases, vaccines save millions of lives each year and avert substantial medical and societal costs associated with prolonged illness. Additionally, vaccines enhance the quality of life by preventing the onset of disease and its complications, thereby contributing to a healthier society.
GCC Vaccine Market Trends:
The GCC market is witnessing substantial growth, driven by increasing health awareness, governmental immunization programs, and advancements in biomedical technologies. Along with this, the rise in preventable infectious diseases and the growing pediatric population are significant factors necessitating continued and expanded vaccine coverage in the region. In addition, economic development is leading to improved healthcare infrastructure and increased healthcare spending in the GCC countries, facilitating wider and more efficient vaccine distribution. Apart from this, recent global health crises have accelerated vaccine research and development, leading to rapid approvals and emergency use authorizations. Furthermore, the GCC's strategic initiatives to achieve self-sufficiency in vaccine production and reduce dependency on imports are also prominent trends shaping the market. These efforts are supported by collaborations between governments and international pharmaceutical giants to enhance local production capabilities, aiming to meet immunization needs promptly and effectively.
GCC Vaccine Market Report Segmentation:
The report is organized into distinct sections as follows:
Breakup by Technology:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
Breakup by Patient Type:
- Paediatric
- Adult
Breakup by Indication:
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis (DPT)
- Tuberculosis
- Haemophilus Influenzae (Hib)
- Typhoid
- Others
- Viral Diseases
- Hepatitis
- Influenza
- Human Papillomavirus (HPV)
- Measles/Mumps/Rubella (MMR)
- Rotavirus
- Herpes Zoster
- Varicella
- Japanese Encephalitis
- Rubella
- Polio
- Rabies
- Dengue
- Others
Breakup by Route of Administration:
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Others
Breakup by Product Type:
- Multivalent Vaccine
- Monovalent Vaccine
Breakup by Treatment Type:
- Preventive Vaccine
- Therapeutic Vaccine
Breakup by End User:
- Hospitals
- Clinics
- Vaccination Centres
- Academic and Research Institutes
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Breakup by Country:
- Saudi Arabia
- UAE
- Qatar
- Bahrain
- Kuwait
- Oman
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=10702&flag=C
Other Key Points Covered in the Report:
- COVID-19 Impact
- Porters Five Forces Analysis
- Value Chain Analysis
- Strategic Recommendations
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments